Praxis Precision Medicines, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Praxis Precision Medicines has filed a definitive proxy statement with the SEC.
NASDAQ
Praxis Precision Medicines reports on a year of growth and execution, highlighting progress in advancing its pipeline of neurological disorder treatments and outlining key milestones for 2025 and beyond.
NASDAQ
Praxis Precision Medicines has filed a definitive proxy statement with the SEC.
NASDAQ
Praxis Precision Medicines is asking stockholders to approve an amendment to its 2020 Stock Option and Incentive Plan to increase the number of shares available for issuance.